retatrutide phase 2 trial Number 1 Top Cardiometabolic Story of 2023: with #retatrutide, a GIP-GLP-1-GCG receptor triple agonist, resulted in a mean weight reduction of 24.2% after 48 weeks. https://t.co/aED6xEFDI3 Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Pay in 4 interest-free payments of $6.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15

























